Scientists at Dana-Farber Cancer Institute have identified a promising new biological pathway that could lead to better treatments for sickle cell disease and beta thalassemia. Using a large genome-wide association study spanning multiple ancestries — including European, African, and Asian populations — researchers pinpointed the BACH2-NRF2 pathway as a key regulator of fetal hemoglobin, the "backup" form of hemoglobin that can compensate for the defective adult version in these disorders.

Here's how it works: BACH2 normally acts as a brake on fetal hemoglobin production. When BACH2 is inhibited, NRF2 steps in to activate fetal hemoglobin genes. Importantly, lab studies showed that pharmacological inhibition of BACH2 successfully increased fetal hemoglobin in human red blood cell precursors — a meaningful proof-of-concept.

Key Takeaways:

• The BACH2-NRF2 pathway is independent of the previously known BCL11A pathway, raising the possibility that targeting both simultaneously could offer even greater benefit to patients
• Pharmacological inhibition of BACH2 has already shown promise in human cell models
• The study underscores the value of diverse, international genetic datasets for uncovering new therapeutic targets

Why it matters: Current gene therapies like Casgevy work by targeting BCL11A, but this new pathway opens an entirely separate avenue for drug-based or gene-editing treatments — potentially expanding options for the millions of patients worldwide living with these debilitating blood disorders.